A photo of Paul Andreassen.

Member, Division of Experimental Hematology & Cancer Biology

Associate Professor, UC Department of Pediatrics

513-636-0499

513-636-3549

Biography & Affiliation

Biography

Paul Andreassen completed his PhD in Experimental Pathology from the University of Washington (Seattle, WA) while working at the Fred Hutchinson Cancer Research Center (Seattle) and the Institut de Biologie Structurale (Grenoble, France). Dr. Andreassen then completed a research fellowship at the Dana-Farber Cancer Institute (Boston, MA) before moving to Cincinnati Children’s Hospital Medical Center in 2004.

Research Interests

Fanconi anemia; breast cancer susceptibility; genetic variants; genome instability; DNA damage responses; replication stress; relationship of DNA repair and chromatin; mitosis; radiation biology; cell biology

Academic Affiliation

Associate Professor, UC Department of Pediatrics

Divisions

Experimental Hematology and Cancer Biology, Cancer and Blood Diseases

Education

BS: Willamette University, Salem, Oregon, 1984.

PhD: University of Washington, Seattle, Washington, 1995.

Publications

Selected Publication

The Initiation of Meiotic Sex Chromosome Inactivation Sequesters DNA Damage Signaling from Autosomes in Mouse Spermatogenesis. Abe, H; Alavattam, KG; Hu, Y; Pang, Q; Andreassen, PR; Hegde, RS; Namekawa, SH. Current Biology. 2020; 30:408-420.e5.

NF1 patient missense variants predict a role for ATM in modifying neurofibroma initiation. Yu, Y; Choi, K; Wu, J; Andreassen, PR; Dexheimer, PJ; Keddache, M; Brems, H; Spinner, RJ; Cancelas, JA; Martin, LJ; et al. Acta Neuropathologica. 2020; 139:157-174.

CRISPR-Cas9 fusion to dominant-negative 53BP1 enhances HDR and inhibits NHEJ specifically at Cas9 target sites. Jayavaradhan, R; Pillis, DM; Goodman, M; Zhang, F; Zhang, Y; Andreassen, PR; Malik, P. Nature Communications. 2019; 10.

SETD2 mutations confer chemoresistance in acute myeloid leukemia partly through altered cell cycle checkpoints. Dong, Y; Zhao, X; Feng, X; Zhou, Y; Yan, X; Zhang, Y; Bu, J; Zhan, D; Hayashi, Y; Zhang, Y; et al. Leukemia. 2019; 33:2585-2598.

Deficiency of the Fanconi anemia E2 ubiqitin conjugase UBE2T only partially abrogates Alu-mediated recombination in a new model of homology dependent recombination. Lewis, TW; Barthelemy, JR; Virts, EL; Kennedy, FM; Gadgil, RY; Wiek, C; Linka, RM; Zhang, F; Andreassen, PR; Hanenberg, H; et al. Nucleic Acids Research. 2019; 47:3503-3520.

XRCC2 (X-ray repair cross complementing 2). Andreassen, PR; Hanenberg, H. Atlas of genetics and cytogenetics in oncology and haematology. 2019; 23:1-7.

PALB2 (partner and localizer of BRCA2). Hanenberg, H; Andreassen, PR. Atlas of genetics and cytogenetics in oncology and haematology. 2018; 22:484-490.

DNA repair-related functional assays for the classification of BRCA1 and BRCA2 variants: a critical review and needs assessment. Toland, AE; Andreassen, PR. Journal of Medical Genetics. 2017; 54:721-731.

Elucidation of the Fanconi Anemia Protein Network in Meoisis and Its Function in the Regulation of Histone Modifications. Alavattam, KG; Kato, Y; Sin, H; Maezawa, S; Kowalski, IJ; Zhang, F; Pang, Q; Andreassen, PR; Namekawa, SH. Cell Reports. 2016; 17:1141-1157.

Complementation of hypersensitivity to DNA interstrand crosslinking agents demonstrates that XRCC2 is a Fanconi anaemia gene. Park, J; Virts, EL; Jankowska, A; Wiek, C; Othman, M; Chakraborty, SC; Vance, GH; Alkuraya, FS; Hanenberg, H; Andreassen, PR. Journal of Medical Genetics. 2016; 53:672-680.